The first-of-its-kind AI-driven, non-blood-contact smart closed-loop diagnostic and treatment platform for heart conditions

Our goal is to redefine how heart failure and structural heart disease are diagnosed, monitored, and treated

Every year, more than 20 million heart failure patients face life-threatening conditions, while existing transplantation options are limited, and ventricular assist devices (VADs) carry a high risk of blood-related complications.

Cambridge CardioMatrix Ltd is pioneering a transformative solution. We are a next-generation cardiovascular technology company based in Cambridge, UK, who are committed to developing soft-robotic cardiac support systems. Our mission is to provide minimally invasive — or even non-invasive — therapeutic solutions that integrate pharmaceuticals, biotechnology, mechanical assistance, and sensing technologies to monitor, protect, and actively support the failing heart externally and continuously in real time, enabling true recovery of failing hearts.

Our breakthrough innovation – based on the fundamental invention of Prof. Xiaohui Zhou – introduces a novel non-blood-contact closed-loop diagnostic and treatment platform for heart conditions. This platform integrates physiological sensing, mechanical assistance, and molecular-targeted intervention into a single implantable system, redefining the diagnosis, monitor and treatment for failing hearts and structural heart diseases.

A New Paradigm for Cardiac Function Management

Advanced cardiac support solutions tailored to individual patient needs

Our technology uses a flexible hydraulic matrix that gently envelops the beating heart to enable：

• Full range of real-time sensing: capturing mechanical, electrophysiological, and biochemical signals of the heart.

• Soft-robotic assisted support: providing automated, controllable, and precise ventricular assistance—while entirely avoiding contact with circulating blood.

• Precise targeted intervention regulated by feedback: delivering immediate intervention through pressure modulation, electrical/magnetic stimulation or localised administration, latest biotechnology etc.

This integrative approach has the potential to fundamentally transform outcomes for patients with:

• Heart Failure

• Cardiomyopathies

• Post-myocardial infarction ventricular remodelling

• Congenital structural heart abnormalities

Cambridge CardioMatrix: Supporting the heart externally, letting the healing come from within...